Clinical Evidence: What the Published Data Reveals
Why UK Patients Compare Wegovy Better Than Mounjaro Results
When evaluating whether Wegovy better than Mounjaro suits your weight management journey, understanding the clinical evidence becomes crucial for UK patients seeking prescription-only medicines. Wegovy (semaglutide) works as a GLP-1 receptor agonist, mimicking your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro (tirzepatide) takes a dual approach, activating both GIP and GLP-1 receptors for potentially different metabolic effects.
The question of Wegovy better than Mounjaro cannot be answered universally, as both treatments demonstrated efficacy in their respective clinical programmes alongside reduced-calorie diets and increased physical activity. NICE TA875 recommends Wegovy with specialist weight management support, whilst Mounjaro received its own NICE guidance through different pathways. Our GPhC-registered clinical team (#9012878) can assess your individual circumstances to determine which prescription-only medicine aligns with your health profile and weight management goals.
Wegovy Pricing and Bundle Value for UK Patients
Understanding the true cost comparison helps clarify whether Wegovy better than Mounjaro represents value for your investment. Single Wegovy pens start at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenience for dose escalation: the Intro Duo (0.25mg & 0.5mg) costs £169.99, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) offers three months' supply for £369.99.
New customers benefit from code FIRST40 applied at checkout to reach these prices, whilst returning customers use DOSE25 for subsequent orders. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, ensuring consistent treatment without multiple orders. When considering Wegovy better than Mounjaro from a practical perspective, our bundle pricing eliminates the uncertainty of individual pen purchases whilst guaranteeing cold-chain delivery maintained at 2-8°C throughout transit.
STEP Trial Evidence: What Clinical Data Shows
The published STEP programme provides robust evidence when evaluating Wegovy better than Mounjaro through peer-reviewed research. STEP 1 (Wilding et al., NEJM, 2021) demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. STEP 3 combined Wegovy with intensive behavioural therapy, supporting approximately clinically studied weight loss in clinical participants.
STEP 5 extended the observation period, showing sustained weight loss of approximately 15.2% at two years, whilst the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events. These findings suggest Wegovy better than Mounjaro may depend on your specific health priorities, as each medication underwent different trial designs with distinct patient populations and endpoints, making direct comparison inappropriate without clinical context.
How Wegovy Works: GLP-1 Mechanism Explained
Understanding the biological basis helps clarify whether Wegovy better than Mounjaro suits your physiology and treatment expectations. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural hormone released by your intestines after eating. This mechanism reduces appetite by acting on brain appetite centres, slows gastric emptying to promote fullness, and may reduce food cravings between meals. The once-weekly FlexTouch pen delivers consistent medication levels, supporting appetite regulation throughout the seven-day dosing interval. Clinical studies demonstrate these effects develop gradually during dose escalation from 0.25mg to the 2.4mg maintenance dose over 16 weeks.
UK Ordering Process: Assessment to Delivery
Accessing Wegovy through EverydayMeds involves a streamlined three-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our prescribers review applications within three working days (or 24 hours with express service), ensuring thorough evaluation before approving this prescription-only medicine. Once approved, next-day delivery maintains cold-chain temperature control from our GPhC-registered pharmacy (#9012878) directly to your address. The process eliminates traditional GP appointment delays whilst maintaining clinical safety through qualified prescriber oversight. Payment processing occurs only after prescription approval, ensuring you're charged exclusively for medications you're clinically suitable to receive.
Storage Advantages and Practical Considerations
Practical factors often influence whether patients find Wegovy better than Mounjaro for long-term treatment adherence and lifestyle integration. Wegovy requires refrigeration at 2-8°C before first use but tolerates room temperature below 30°C for up to six weeks once removed from the fridge. This storage advantage exceeds Mounjaro's 21-day room temperature limit, providing greater flexibility for travel, work schedules, or temporary accommodation changes. The FlexTouch pen system offers intuitive operation with clear dose indication and automatic needle insertion. Dose escalation follows a mandatory schedule over 16 weeks, allowing gradual tolerance development whilst monitoring individual response to treatment. Missing doses requires specific guidance to maintain therapeutic continuity without compromising safety or efficacy.
Cardiovascular Benefits: SELECT Trial Findings
The SELECT cardiovascular outcomes trial provides unique evidence when considering Wegovy better than Mounjaro for patients with existing heart disease risk factors. Published data demonstrated 20% reduction in major cardiovascular events among participants with established cardiovascular disease or multiple risk factors, representing a hazard ratio of 0.80 compared to placebo. This finding extends beyond weight management into cardiovascular protection, potentially influencing treatment choice for patients with diabetes, hypertension, or previous cardiac events.
These cardiovascular benefits emerged alongside the weight management effects, suggesting Wegovy's mechanism may offer dual therapeutic value for appropriate patients. However, determining whether Wegovy better than Mounjaro suits your cardiovascular profile requires individual clinical assessment, as both medications carry specific contraindications and monitoring requirements that vary between patients.
Making Your Treatment Decision with Expert Guidance
Ultimately, deciding whether Wegovy better than Mounjaro fits your circumstances requires personalised clinical assessment rather than generalised comparisons. Both medications are available through EverydayMeds following appropriate prescriber evaluation, ensuring you receive treatment aligned with your medical history and weight management objectives. Our clinical team considers factors including your BMI, comorbidities, medication tolerance, lifestyle requirements, and treatment preferences when recommending suitable options. Starting your assessment takes three minutes online, with prescriber review ensuring clinical appropriateness before confirming your order. Use code FIRST40 at checkout for new customer pricing, or DOSE25 for returning patients, accessing the same clinical-grade treatment available through traditional healthcare pathways with enhanced convenience and next-day delivery.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
